Our approach works in the extracellular matrix, by triggering B cells response to produce specific antibodies to neutralize the targeted growth factors. Removal of specific growth factors involved in cancer signalling prevent uncontrolled proliferation.
Data from studies suggest that this approach is less toxic than other approved treatments, making our therapeutics well tolerated with a mild toxicity profile when compared to other leading immune-therapies approach in the market.